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Oral candidiasis is particularly evident not only in cancer patients receiving 
chemotherapy, but also in elderly people with xerostomy. It is a fungal infection caused by 
Candida species such as Candida albicans. In general, Candida is an opportunistic 
pathogen, causing infections in immunocompromised people and in some cases when 
natural microbiota is altered. One of major virulence capacity of C. albicans is its ability to 
adapt to a variety of different habitats and the consequent formation of surface-attached 
microbial communities known as biofilms. Along with the current limited repertoire of 
clinically available antifungals, the drawbacks associated with them such as development 
of resistance in the pathogen, limited clinical efficacy and poor bioavailability, demand for 
the development of new antifungal agents. Chitosan, a natural derivative of chitin, is a 
polysaccharide that was proved to possess a broad spectrum of antimicrobial activity that 
encompasses fungi, yeast and bacteria. Possesses high biocompatibility and anti-
inflammatory capacity and while recent studies have revealed a significant antibiofilm 
activity upon several microorganism, including C. albicans, little is known when regarding 
the impact of chitosan upon the adhesive process or mature biofilms. With that in mind, 
the purpose of this work was to evaluate, in vitro, the capability of chitosan to inhibit C. 
albicans growth and biofilm formation. 
The results obtained showed that chitosan is capable of inhibiting C. albicans growth 
(HMW - 1mg/ml; LMW – 3 mg/ml). At sub-MIC concentrations (HMW -0.5 and 0.25 
mg/ml; LMW - 1.75 and 0.75 mg/ml) they showed biofilm formation inhibition 
(percentages above 90%) and reduction of mature biofilms formation by ca. 65%. 
Additionally, chitosan was also capable of inhibiting C. albicans adhesion (ca. 95%). 
These results display the potential of this molecule to be used in the oral cavity and in 
particular, in the treatment of oral candidiasis. 
  
